Back to discover
Drug

Apatinib

In clinical development
Emerging researchLate-stage development

Also known as Rivoceranib, Apartinib.

RxNorm815252ChEMBLCHEMBL3186534UNII5S371K6132
1
Research papers
39
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized, Open-Label, Multi-Center, Phase Ⅲ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Clinical trial2026-07-31Primary completion · ClinicalTrials.gov

An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of the LM-302 Combination With Other Anti-tumor Treatment in Subjects With CLDN18.2-positive Advanced Gastro-Intestinal Cancer.

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Camrelizumab, Apatinib Plus Hepatic Arterial Infusion Chemotherapy Versus Camrelizumab and Apatinib for Hepatocellular Carcinoma With Portal Vein Invasion: a Randomized, Open-label, Multicentre Trial

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Phase II Clinical Study of Adebrelimab Combined With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules in the Treatment of Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma That Failed First-line Immunotherapy Combined With Chemotherapy

Clinical trial2026-06-04Results expected Q1 2028 · ClinicalTrials.gov

Immune Checkpoint Inhibitors and Anti-Vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without Interventional Therapy for Advanced HCC

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Liposomal Doxorubicin Hydrochloride and Apatinib in Combination with Camrelizumab for the First-line Treatment of Advanced/unresectable Dedifferentiated Liposarcoma

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)

Clinical trial2026-05-31Primary completion · ClinicalTrials.gov

Phase II Clinical Study of Adebrelimab Plus Apatinib and SOX Regimen for Conversion Therapy of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial2026-04-22Results expected Q1 2028 · ClinicalTrials.gov

Clinical Study of SHR1701 in Combination With CAPOX and SHR2554 or Apatinib for First-line Treatment of Advanced Gastric Cancer

Clinical trial2026-04-16Results expected Q3 2027 · ClinicalTrials.gov

A Prospective Exploratory Study of SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial2026-03-11Results expected Q2 2028 · ClinicalTrials.gov

A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung

Clinical trial2026-03-03Results posted · ClinicalTrials.gov

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.

Research2020-10-21Clinical cancer research : an official journal of the American Association for Cancer Research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Apatinib
Aliases & brands
RivoceranibApartinib
RxNorm CUI
815252
ChEMBL ID
CHEMBL3186534
UNII
5S371K6132

Clinical trials

195 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
195
registered trials across all phases
LATEST COMPLETION 2023
39
Active studies
30
Recruiting
46
Late-stage (III+)
31
Completed
125
Discontinued
PHASE DISTRIBUTIONn = 195
Phase 110Phase 1 / 211Phase 2128Phase 2 / 311Phase 321Phase 45Phase N / A9

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Prospective, Multicenter, Randomized Controlled Study of Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Unknown statusPH IVUnion Hospital, Tongji Medical College, Huazhong University of Science and Technologyn=602023

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study

WithdrawnPH IVXinqiao Hospital of Chongqing2022

A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib

Unknown statusPH IVSun Yat-sen Universityn=2172021

A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Unknown statusPH IVZhengzhou Universityn=1002019

Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies.

CompletedPH IVShandong Cancer Hospital and Instituten=382018

Recent completions

Trials that read out recently, adding to the completed evidence base.

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial

CompletedPH IShanghai Jiao Tong University School of Medicinen=212023

A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy

CompletedPH IIIJiangsu HengRui Medicine Co., Ltd.n=5432023

A Randomized, Open-label, Multi-center Phase III Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

CompletedPH IIIJiangsu HengRui Medicine Co., Ltd.n=8852023

Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study.

CompletedPH IIBeijing Friendship Hospitaln=282023

Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

CompletedPH IIIHuashan Hospitaln=632022

SHR-1210, a Novel Anti-pd-1 Antibody, in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: a Single-arm, Open Label, Multi-center, Phase II Study

CompletedPH IISun Yat-sen Universityn=452022

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2021 · 455 cites
Recent papers

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2021 · 455 cites
Journals, researchers & institutions
Top journals
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
Leading researchers
  • Chen X1
  • Gu K1
  • Gu S1
  • Li E1
  • Li L1
  • Liu J1
  • Ma K1
  • Mao X1
Leading institutions
free-text, unnormalised
  • 900 Hospital of the Joint Logistics Support Force1
  • Cancer Center1
  • Clinical Research & Development1
  • Guangxi Medical University Affiliated Tumor Hospital1
  • Harbin Medical University Cancer Hospital1
  • Henan Cancer Hospital1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Camrelizumab

Studied across 2 of the same disease areas as Apatinib in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials